Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule

Executive Summary

The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003
Advertisement

Related Content

“Functional Equivalence” For 2004: Aranesp OPPS Payment Is 78% Of AWP
Procrit, Aranesp Reimbursement Adjusted; CMS Splits The Difference
CMS Proposed OPPS Rule Sets Reduced Payment Level During Generic Erosion
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
CMS “Functional Equivalence” Standard Targeted In Medicare Bills
“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?
Aranesp Versus Procrit: Amgen Will Submit Comparative Data to CMS
Baxter/Alpha Aralast Launch Will Ease Bayer Prolastin Supply Pressure
Aranesp coverage decision
Aranesp coverage decision draws Congressional interest
Advertisement
UsernamePublicRestriction

Register

PS040710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel